Evidence map›Paper›PMID 30241182›Full record

ArticleJournal of global oncology2018

Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer.

Manuel Caitano Maia, Allan A Lima Pereira, Liana Valente Lage, Natalia Moreno Fraile, Victor Van Vaisberg, Guilherme Kudo, Romualdo Barroso-Sousa, Diogo Assed Bastos, Carlos Dzik

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of global oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05471427 (Predictive fActors for toleraNce to Taxane Based CHemotherapy In Older adultS Affected by mEtastatic Prostate Cancer, a Prospective Observational Study), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05471427 completednot on this mapstarted 2020, after this paper: background citation

Predictive fActors for toleraNce to Taxane Based CHemotherapy In Older adultS Affected by mEtastatic Prostate Cancer, a Prospective Observational Study (ANCHISES)

TypeobservationalSponsorAzienda Ospedaliero-Universitaria CareggiRan2020 to 2022Enrolled118ConditionsElderly Patients, Metastatic Prostate CancerArmsTaxane chemotherapy
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Safety of PSMA-Targeted Molecular Radioligand Therapy withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Trial
  2. Article
  3. Article
  4. Article
  5. [Concepts in geriatric uro-oncology].Der Urologe. Ausg. A · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 6 countries.

Manuel Caitano MaiaAll authors: Universidade de São Paulo, São Paulo, Brazil.
Allan A Lima PereiraAll authors: Universidade de São Paulo, São Paulo, Brazil.
Liana Valente LageAll authors: Universidade de São Paulo, São Paulo, Brazil.
Natalia Moreno FraileAll authors: Universidade de São Paulo, São Paulo, Brazil.
Victor Van VaisbergAll authors: Universidade de São Paulo, São Paulo, Brazil.
Guilherme KudoAll authors: Universidade de São Paulo, São Paulo, Brazil.
Romualdo Barroso-SousaAll authors: Universidade de São Paulo, São Paulo, Brazil.
Diogo Assed BastosAll authors: Universidade de São Paulo, São Paulo, Brazil.
Carlos DzikAll authors: Universidade de São Paulo, São Paulo, Brazil.
Janssen (Switzerland) · CHRoche (Switzerland) · CHSanofi (France) · FRBristol-Myers Squibb (Germany) · DEJanssen (France) · FRNovartis (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLimited data are available about the tolerability and clinical outcomes of elderly patients with metastatic castration-resistant prostate cancer (mCRPC) who are treated with docetaxel. We evaluated the efficacy and safety of docetaxel as first-line chemotherapy for patients with mCRPC who were treated in our institution. MATERIALS AND

methodsWe retrospectively identified patients with mCRPC and a Karnosfky performance status of 60% or greater treated with docetaxel on any schedule as first-line chemotherapy between 2008 and 2013. The primary end point was a comparison of median overall survival (OS) according to age in this population. Secondary end points were comparisons of the rates of severe toxicities, prostate-specific antigen (PSA) decline of 50% or greater, and time to progression (TTP). Results were stratified by three age groups: younger than 65 years, 65 to 74 years, and 75 years or older.

resultsAmong the 197 patients included, 68 (34%) were younger than 65 years, 85 (43%) were 65 to 74 years, and 44 (22%) were 75 years or older. The mean number of comorbidities was not different among groups (1.19 v 1.32 v 1.43; P = .54). Patients younger than 65 years received a higher cumulative dose of docetaxel (450 mg/m

conclusionAdministration of docetaxel in elderly patients who had good performance status was well tolerated. Rates of PSA decline and TTP were similar to those of younger patients, but median survival was lower.

Indexed as

AgedAged, 80 and overAntineoplastic AgentsDocetaxelHumansMaleProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantRetrospective StudiesTreatment OutcomeAntineoplastic AgentsDocetaxelProstate-Specific Antigen

Identifiers

PMID30241182
PMCPMC6180794
OpenAlexW2600343577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.